期刊文献+

循环肿瘤细胞在转移性乳腺癌中的表达及其与多种血清肿瘤标志物的关系 被引量:6

Expression of circulating tumor cells in metastatic breast cancer patients and its relationship with multiple serum tumor markers
下载PDF
导出
摘要 目的探讨转移性乳腺癌的循环肿瘤细胞(CTC)和血清肿瘤标志物(CEA、CAl53和CAl25)的表达水平以及两者之间的相关性。方法采用CellSearch自动检测系统检测93例转移性乳腺癌患者开始新治疗前的循环肿瘤细胞(CTC),同时采用电化学发光法检测这些患者血清肿瘤标志物(CEA、CAl53和CAl25)的表达水平。结果CTC阳性率为60%(56/93),与患者激素受体的状态、Her-2的状态、既往治疗的线数以及内脏转移无关。CEA的阳性率为56%(52/93),ER或PR阳性的患者CEA的阳性率更高(x2=4.550,P=0.045),与Her-2的状态、既往治疗的线数以及内脏转移无关;CAl53的阳性率为47%(44/93),与患者激素受体的状态、Her-2的状态、既往治疗的线数以及内脏转移无关;CAl25的阳性率为4l%(38/93);既往治疗大于等于二线的患者CAl25的阳性率更高(X2=4.501,P=0.038),与患者激素受体的状态、Her-2的状态以及是否有内脏转移无关。CTC和CEA之间呈正相关(r=0.296,P=0.004);CTC和CAl53之间呈正相关(r=0.286,P=0.005);CTCs和CAl25两者之间无相关性(r=0.184,P=0.077)。结论转移性乳腺癌患者的循环肿瘤细胞(CTC)检出率高,而且与血清肿瘤标志物(CEA和CAl53)有明显相关性,提示联合检测转移性乳腺癌的循环肿瘤细胞(CTC)和血清肿瘤标志物(CEA和CAl53)可能会对其治疗决策有所帮助,同时CTC有可能成为转移性乳腺癌新的治疗靶点。 Objective To investigate the expression of circulating tumor cells in metastatic breast cancer and its relatonship with CEA,CA153 and CA125. Methods The Cell Search system was used to detect the expressions of CTCs before new line therapy, meanwhile the electroehemiluminescence was used to detect the expression of CEA, C153 and CA125 in 93 patients with metastatic breast cancer. Results 60% (56/93)metastatic breast cancer patients with ≥ 1 CTC/7.5 mL at baseline. The CTC positivity was not correlated with hormone receptor status,Her- 2 status, lines of previous treatment and visceral metastasis. The CEA positivity was 56% ( 52/93 ). It was associated with ER or PR - positive ( X2 = 4.550, P = 0.045 ) , and was not correlated with Her - 2 status ,lines of previous treatment and visceral metastasis. CA153 positivity was 47% (44/93). It was not correlated with hormone receptor status, Her -2 status,lines of previous treatment and visceral metastasis. CA125 positivity was 41% (38/93) , and it was associated with over one- line previous treatment( X2 = 4.501, P = 0. 038 ), However, CA125 positivity was not correlated with hormone receptor status, Her- 2's status and visceral metastasis. The CTC was positively correlated with CEA(r =0. 296,P =0. 004). It was positively correlated with CA153 (r=0.286,P=0.005) ,and not correlated with CA125(r =0. 184,P =0.077). Conclusion The circulatingtumor cells(CTCs) positivity was high in patients with metastatic breast cancer, but also its positivity has correlation with CEA and CA153. Our study indicated that detection of circulating tumor ceils combination with CEA and CA153 in metastatic breast cancer may be helpful for therapy, meanwhile the CTC may become a potential therapy target for metastatic breast cancer.
出处 《实用肿瘤学杂志》 CAS 2012年第3期220-224,共5页 Practical Oncology Journal
关键词 乳腺肿瘤 循环肿瘤细胞 肿瘤标记物 相关性 电化学发光 Breast neoplasms Circulating tumor cells Tumor markers Correlation Electrochemiluminescence
  • 相关文献

参考文献15

  • 1E. A. Eisenhauer, P. Therasse, J. Bogaerts, et al. New re- sponse evaluation criteria in solid tumours: Revised RE- CIST guideline (version 1. 1 ) [J]. European Journal of Cancer,2009,45 ( 2 ) :228 - 247.
  • 2AshworthTR. A case of cancer in which ceils similar to those in the tumours were seen in the blood after death[J]. Aust- Med J,1869,(14) :146 -149.
  • 3Tibbe AG, de Grooth BG, Greve J, et al. Cell analysis system based on immunomagnetic cell selection and alignment fol- lowed by immunofluorescent analysis using compact disk technologies[J]. Cytometry ,2001, (43) :31 - 37.
  • 4Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases[J]. Clin Cancer Res,2004, (10) :6897 -6904.
  • 5Massimo Cristofanilli, M. D, G. Thomas Budd, et al. Circu- lating Tumor Cells, Disease Progression, and Survival in Me- tastatic Breast Cancer [J]. N Engl J Med,2004,351:781 - 791.
  • 6Jean - Yves Pierga, Franqois - Clement Bidard, Claire Ma- thiot, et al. Randomized Trial and Locally Advanced Breast Cancer in a Phase Ⅱ Relapse After Neoadjuvant Chemo- therapy in Large Operable Circulating Tumor Cell Detection Predicts Early Metastatic [J]. Clin Cancer Res, 2008, (14) :7004 -7010.
  • 7A. Giordanol, M. Giuliano, M. De Laurentiis, et al. Circulat- ing tumor cells in immunohistochemical subtypes of meta- static breast cancer: lack of prediction in HER2 - positive disease treated with targeted therapy [J]. Anna1 of oncology,.2012,23(5):1144 -1150.
  • 8Dorit Laessig, Dorothea Nagel, Volker Helnemann, et al. Im- portance of CEA and CA 15 - 3 during Disease Progres- sionin Metastatic Breast Cancer Patients[J]. ANTICANCER RESEARCH ,2007,27 (4A) : 1963 - 1968.
  • 9Duffy MJ, Evoy D, McDermott EW, et al. CA 15 -3: uses and limitation as a biomarker for breast cancer [J]. Clin Chim Acta,2010,411 (23 -24) :1869 - 1874.
  • 10仲崇明,周彦,卞光荣,孙志超,贾惠英,鲁凯,姚壮凯.乳腺癌患者血清肿瘤标志物与免疫组化标志物相关性的研究[J].实用肿瘤学杂志,2010,24(3):224-226. 被引量:4

二级参考文献8

  • 1涂植光.依托现代科学管理和技术 开展肿瘤标志物研究和应用[J].中华检验医学杂志,2006,29(4):289-292. 被引量:15
  • 2Sturgeon C.Practice guidelines for tumor marker use in the clinic[J].Clin Chem,2002,48(8):1151-1159.
  • 3Jukkola A,Bloigu R,Soine Y,et al.C-erbB2 positivity is a factor for poor prognosis in breast cancer and poor response to hornmonal or chemotherapy treatment in advancer disease[J].Eur J Cancer,2001,37(3):347-354.
  • 4Konecny G,Pauletti G,Pegram M,et al.Quantitative associ-ation between HER-2/neu and steroid hormone receptors in hormone receptor-positive Primary breast cancer[J].J Natl Cancer Inst,2003,95(2):142-153.
  • 5Ravdin PM,Chamness GC.The C-erbB2 proto-oncogene as a prognostic and predictive marker in breast cancer:Aparadigm for the development of other macromolecular markers-A review[J].Gene,1995,159(1):19-24.
  • 6宁连胜,方志沂.现代乳腺疾病治疗学[M].第2版,北京:人民卫生出版社,2006:455-461.
  • 7董永红,吕云福,匡玉庭,张志德,高敏,郭钟行.乳腺癌c-erbB-2 DNA的预后价值[J].第四军医大学学报,2002,23(21):1933-1936. 被引量:6
  • 8杨金巧.乳腺癌的内分泌治疗及研究进展[J].中国普外基础与临床杂志,2004,11(1):12-13. 被引量:15

共引文献3

同被引文献20

  • 1Gianni L. The future of targeted therapy: combining novel agents[J]. Oncology, 2002 ,63 Suppl 1:47 — 56.
  • 2Soria J C,Blay J Y,Spano J P, et al. Added value of moleculartargeted agents in oncology[J]. Ann Oncol, 2011,22 (8): 1703 —1716.
  • 3Puglisi F,Minisini A M, De Angelis C,et al. Overcoming treat-ment resistance in HER—2 —positive breast cancer: potential strat-egies[J]. Drugs, 2012,72 (9) : 1175-1193.
  • 4Masuda H,Zhang D, Bartholomeusz C,et al. Role of epidermalgrowth factor receptor in breast cancer [J]. Breast Cancer ResTreat, 2012,136 (2): 331—345.
  • 5Wu J M,Halushka M K,Argani P. Intratumoral heterogeneity ofHER—2 gene amplification and protein overexpression in breastcancer[J]. Hum Pathol, 2010,41 -6) : 914 — 917.
  • 6Gerlinger M, Rowan A J, Horswell S,et al. Intratumor heteroge-neity and branched evolution revealed by multiregion sequencing[J]. N Engl J Med, 2012,366 (10): 883 — 892.
  • 7Amir E, Miller N,Geddie W, et al. Prospective study evaluatingthe impact of tissue confirmation of metastatic disease in patientswith breast cancer[J]. J Clin Oncol, 2012,30(6):587 — 592.
  • 8Balic M, Williams A,Lin H, et al. Circulating Tumor Cells: FromBench to Bedside[J]. Annu Rev Med, 2013 ,64 : 31 — 44.
  • 9Franken B, Degroot M R, Mastboom W J, et al. Circulating tumorcells- disease recurrence and survival in newly diagnosed breastcancer[J]. Breast Cancer Res, 2012 ,14(5) :R133.
  • 10Sinha G. Circulating Tumor Cells in Early—Stage Breast Cancer[J]. J Natl Cancer Inst, 2012,104(22): 1693—1694.

引证文献6

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部